title: Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
abstract: Despite growing interest in thrombolytic agents to treat submassive pulmonary embolism, their role in this scenario remains controversial. Needed is a way to identify patients with this condition who are at risk of clinical deterioration and who would benefit from thrombolytic therapy. Here, we review the use of thrombolytic agents in submassive pulmonary embolism to help distinguish the risk and benefits of this therapy.
authors.affiliation: Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA. E-mail: aliataya@gmail.com.
authors.forename: Ali
authors.initials: A
authors.lastname: Ataya
authors.affiliation: Pulmonary Hypertension Program, Department of Pharmacy, University of Florida, Gainesville, FL, USA.
authors.forename: Jessica
authors.initials: J
authors.lastname: Cope
authors.affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA.
authors.forename: Abbas
authors.initials: A
authors.lastname: Shahmohammadi
authors.affiliation: Pulmonary Hypertension Program, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, USA.
authors.forename: Hassan
authors.initials: H
authors.lastname: Alnuaimat
mesh_terms: D006801:Humans; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000188:drug therapy*; D015912:Thrombolytic Therapy